Literature DB >> 15356040

Overexpression of 11beta-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins.

Katja Kannisto1, Kirsi H Pietiläinen, Ewa Ehrenborg, Aila Rissanen, Jaakko Kaprio, Anders Hamsten, Hannele Yki-Järvinen.   

Abstract

11beta-Hydroxysteroid dehydrogenase type 1 (11beta-HSD-1) catalyzes the interconversion of inactive cortisone to active cortisol. Overexpression of 11beta-HSD-1 in murine adipose tissue results in glucocorticoid receptor (GR)alpha overexpression, central obesity, and insulin resistance. It is controversial whether 11beta-HSD-1 or GRalpha expression are increased in human adipose tissue in obesity. We studied effects of acquired obesity on 11beta-HSD-1 gene (real-time PCR) and protein (Western blotting) expression in sc adipose tissue in 17 monozygotic twin pairs aged 24-27 yr with a mean intrapair difference in body mass index (BMI) of 3.8 kg/m(2) (range 0.4-10.1 kg/m(2)). Intrapair correlations were calculated to study effects of acquired obesity on 11beta-HSD-1 expression. Western blot analysis of adipose tissue homogenates identified approximately 50- and approximately 68-kDa proteins specific for 11beta-HSD-1. Both structural forms correlated positively with 11beta-HSD-1 mRNA concentrations. Intrapair differences in 11beta-HSD-1 mRNA, and the 50- and 68-kDa proteins in sc adipose tissue correlated positively with those in BMI (kilograms per square meter) (r = 0.78 for 11beta-HSD-1 mRNA, P = 0.0002; r = 0.87 for the 11beta-HSD-1 50-kDa protein, P = 0.0003; and r = 0.62 for the 11beta-HSD-1 68-kDa protein, P = 0.033), total body fat (percent) (r = 0.65, P = 0.005; r = 0.83, P = 0.001; and r = 0.69, P = 0.013, respectively) and sc fat (cubed centimeters) (r = 0.66, P = 0.004; r = 0.94, P = 0.0001; and r = 0.71, P = 0.009, respectively). Furthermore, 11beta-HSD-1 mRNA and 50-kDa protein expression, but not 68-kDa protein expression, correlated positively with intrapair differences in intraabdominal fat mass (cubed centimeters) (r = 0.62, P = 0.008; r = 0.69, P = 0.013; r = 0.48, P = 0.112) and serum fasting insulin concentration (milliunits per liter) (r = 0.76, P = 0.0004; r = 0.60, P = 0.037; and r = 0.43, P = 0.160, respectively). Intrapair differences in GRalpha expression were significantly inversely correlated with those in BMI and total and sc fat mass. In conclusion, expression of 11beta-HSD-1 in sc adipose tissue is increased in human acquired obesity and is closely related to accumulation of sc and intraabdominal fat and features of insulin resistance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15356040     DOI: 10.1210/jc.2004-0153

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  41 in total

Review 1.  Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 in obesity.

Authors:  Deborah J Wake; Brian R Walker
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

Review 2.  11beta-HSD1, inflammation, metabolic disease and age-related cognitive (dys)function.

Authors:  Karen E Chapman; Jonathan R Seckl
Journal:  Neurochem Res       Date:  2007-10-25       Impact factor: 3.996

3.  Acute in vivo effects of insulin on gene expression in adipose tissue in insulin-resistant and insulin-sensitive subjects.

Authors:  J Westerbacka; A Cornér; K Kannisto; M Kolak; J Makkonen; E Korsheninnikova; T Nyman; A Hamsten; R M Fisher; H Yki-Järvinen
Journal:  Diabetologia       Date:  2005-12-16       Impact factor: 10.122

Review 4.  Genetic determinants of cardiometabolic risk: a proposed model for phenotype association and interaction.

Authors:  Piers R Blackett; Dharambir K Sanghera
Journal:  J Clin Lipidol       Date:  2012-04-22       Impact factor: 4.766

Review 5.  Dissection of glucocorticoid receptor-mediated inhibition of the hypothalamic-pituitary-adrenal axis by gene targeting in mice.

Authors:  Gloria Laryea; Lisa Muglia; Melinda Arnett; Louis J Muglia
Journal:  Front Neuroendocrinol       Date:  2014-09-27       Impact factor: 8.606

6.  The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy.

Authors:  Julio Rosenstock; Salomon Banarer; Vivian A Fonseca; Silvio E Inzucchi; William Sun; Wenqing Yao; Gregory Hollis; Robert Flores; Richard Levy; William V Williams; Jonathan R Seckl; Reid Huber
Journal:  Diabetes Care       Date:  2010-04-22       Impact factor: 17.152

7.  Clinical significance of CYP2C19 polymorphisms on the metabolism and pharmacokinetics of 11β-hydroxysteroid dehydrogenase type-1 inhibitor BMS-823778.

Authors:  Yaofeng Cheng; Lifei Wang; Lisa Iacono; Donglu Zhang; Weiqi Chen; Jiachang Gong; William Griffith Humphreys; Jinping Gan
Journal:  Br J Clin Pharmacol       Date:  2017-10-04       Impact factor: 4.335

8.  Overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in hepatic and visceral adipose tissue is associated with metabolic disorders in morbidly obese patients.

Authors:  René Baudrand; Cristian A Carvajal; Arnoldo Riquelme; Mauricio Morales; Nancy Solis; Margarita Pizarro; Alex Escalona; Camilo Boza; Gustavo Pérez; Angélica Domínguez; Marco Arrese; Carlos E Fardella
Journal:  Obes Surg       Date:  2009-08-19       Impact factor: 4.129

9.  Prenatal programming of metabolic syndrome in the common marmoset is associated with increased expression of 11beta-hydroxysteroid dehydrogenase type 1.

Authors:  Moffat J Nyirenda; Roderick Carter; Justin I Tang; Annick de Vries; Christina Schlumbohm; Stephen G Hillier; Frank Streit; Michael Oellerich; Victor W Armstrong; Eberhard Fuchs; Jonathan R Seckl
Journal:  Diabetes       Date:  2009-08-31       Impact factor: 9.461

10.  Chronic maternal dietary chromium restriction modulates visceral adiposity: probable underlying mechanisms.

Authors:  Inagadapa J N Padmavathi; K Rajender Rao; Lagishetty Venu; Manisha Ganeshan; K Anand Kumar; Ch Narasima Rao; Nemani Harishankar; Ayesha Ismail; Manchala Raghunath
Journal:  Diabetes       Date:  2009-10-21       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.